[1] |
ZHANG Qiang, ZHENG Huajun, LI Quan.
Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480.
|
[2] |
WANG Dan, YAN Xiaoli, ZHANG Yuan.
Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
|
[3] |
ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi.
Interactions and clinical significance of gut microbiota and levothyroxine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
|
[4] |
CAI Zichun, JIANG Yuanzhen, ZHANG Chunsheng, LI Jiming.
Research progress and application prospects of circRNA in cardiovascular diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 397-404.
|
[5] |
CHEN Qian, WANG Yafeng, DUO Delong, CHANG Ya'e, YAN Yingjun, DUAN Kunkun.
Trigliptin succinate have an effect on gut microbiota of type 2 diabetic mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 15-24.
|
[6] |
WANG Yaya, CHU Zixuan, YANG Junling, Olajide E. Olaleye, HE Rongrong, LI Muzi, CHENG Chen, LI Chuan.
Potential health benefits of resveratrol: a pharmacokinetics-caused conundrum
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 931-954.
|
[7] |
WU Rongrong, CHEN Zhiqiang, JIA Yifei, CHEN Hongqi, WANG Panpan, YAN Ru.
Applications of BGUSs inhibition in tumor prevention and chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 964-974.
|
[8] |
ZHENG Binjie, LIU Na, ZENG Xiangchang, HUANG Xinyi, CHEN Lulu, OU-YANG Dongsheng.
Effects of gut microbiota on pharmacokinetics and its consideration in the evaluation of the consistency of quality and efficacy of generic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 662-671.
|
[9] |
WANG Fengling, MENG Xiangyun, CHEN Zhengxu, CAO Rongjuan, HE Zhengmin, YE Xi, WANG Cong, LI Qi.
Analysis on genetic polymorphism of SLCO1B1 and ApoE in patients with cardiovascular diseases of Han nationality in Anhui area and its clinical significance for individualized use of statins
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 40-48.
|
[10] |
YANG Ming, DONG Xiaowen, HONG Huashan.
Statins for primary prevention of atherosclerotic cardiovascular disease in people 75 years of age and older
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1074-1080.
|
[11] |
FANG Qing, OU-YANG Dongsheng.
Trimethylamine N-oxide and inflammatory disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 318-326.
|
[12] |
XIONG Qin-mei, HONG Kui.
Survey on anticoagulant therapy in pregnant women with cardiovascular disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 223-227.
|
[13] |
WU Wei-hua, HU Chang-ping.
Role of microRNA-21 in cardiovascular diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 709-714.
|
[14] |
SUN An-xiu, LIU Yang-chen, GU Ling, LV Jian-feng, FAN Hui, SHI Ai-ping, WANG Lin.
Intervention study on compliance of aspirin in clinical practice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1156-1159.
|
[15] |
ZHU Yu, WU Mei-hua.
Advances in nonsteroidal antiinflammatory drugs and cardiovascular disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(3): 350-354.
|